🔗 Share this article

Given that the US proceeds with unprecedented revisions to its vaccination schedules, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines in the global health crisis and has focused upon potential fatalities following COVID-19 vaccination in her short time at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Program

Public health authorities planned to unveil sweeping changes to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of alignment with much of the international standard with little proof for benefit. This reveal has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the center this calendar year.

Consolidating Power at the FDA

This interim role could signify a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting some childhood shot schedules in the US to become more similar to Denmark's approach, a society with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – typically the purview of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has no obvious experience in drug development, regulation or administrative roles, which has been customary for former leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a major agency. She has no expertise in drug approvals.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed the center have had.”

This division has an vast workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and every single one need to be supervised,” she explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a major administrative component to the job, which oversees more than 5,000 staff members. “It’s a enormous management job, if you do it right,” she concluded.

Response and Disputed Programs

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a spokesperson said that the “concerns stem from incorrect presumptions”.

“This background is consistent with the duties of her job,” the representative explained, citing the period Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's controversial expedited review system, a controversial expedited therapy clearance system that reportedly concerned her preceding directors. “How are these drugs being selected for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of confidentiality going on at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards laxer regulations of most medications, aside from shots.”

Established Past Work on Immunizations

With immunizations, Høeg has a clearer, if troubling, past, critics said. She authored a analysis using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership encompassed altering regulations for new vaccines and halting “optional” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from receiving Covid vaccinations.

“She is an complete true believer who starts off with her preconceived notions and works backwards to fit the science in a highly disingenuous, untruthful manner,” Howard said.

Taking Control and a “Push for Payback”

Høeg became part of fellow dissenters, {like|